Lake Stephanie, Hayashi Kanna, Buxton Jane, Milloy M-J, Dong Huiru, Wood Evan, Montaner Julio, Kerr Thomas
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.
British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.
Drug Alcohol Depend. 2015 Nov 1;156:297-303. doi: 10.1016/j.drugalcdep.2015.09.026. Epub 2015 Sep 30.
Prescription opioid (PO) use by people who inject drugs (PWID) is a growing public health concern. Non-fatal overdose remains a leading source of morbidity among PWID, however, little is known about the relationship between PO injection and non-fatal overdose in this population. In this study we sought to examine the impact of PO injection on non-fatal overdose among PWID from Vancouver, Canada.
Data were derived from two open prospective cohorts of PWID for the period of December, 2005 to May, 2014. Multivariable generalized estimating equations were used to examine the odds of overdose among those who injected: POs; heroin; and POs and heroin.
In total, 1660 PWID (33.7% women) participated in this study. In multivariable analyses, in comparison to those who were injecting non-opioid drugs, exclusive PO injection was not significantly associated with non-fatal overdose (adjusted odds ratio [AOR]: 1.17, 95% confidence interval [CI]: 0.74-1.86). The odds of non-fatal overdose were elevated for heroin injection (AOR: 1.72, 95% CI: 1.31-2.27), but were greatest for those who injected both heroin and POs (AOR: 2.46, 95% CI: 1.83-3.30).
Compared to injecting non-opioids, injecting POs exclusively did not increase risk of non-fatal overdose; however, injecting both POs and heroin doubled the risk. This may reflect consistencies in drug potency and composition when POs are used, as well as unique characteristics of exclusive PO injectors. Our findings call for the continued scale-up of evidence-based overdose prevention interventions for people who inject opioids, including POs.
注射吸毒者(PWID)使用处方阿片类药物(PO)是一个日益严重的公共卫生问题。非致命性过量用药仍然是PWID发病的主要原因,然而,对于该人群中PO注射与非致命性过量用药之间的关系知之甚少。在本研究中,我们试图探讨PO注射对加拿大温哥华PWID非致命性过量用药的影响。
数据来自2005年12月至2014年5月期间两个开放的PWID前瞻性队列。使用多变量广义估计方程来检验注射以下药物者过量用药的几率:PO;海洛因;PO和海洛因。
共有1660名PWID(33.7%为女性)参与了本研究。在多变量分析中,与注射非阿片类药物者相比,单纯注射PO与非致命性过量用药无显著关联(调整后的优势比[AOR]:1.17,95%置信区间[CI]:0.74 - 1.86)。注射海洛因导致非致命性过量用药的几率升高(AOR:1.72,95% CI:1.31 - 2.27),但同时注射海洛因和PO者的几率最高(AOR:2.46,95% CI:1.83 - 3.30)。
与注射非阿片类药物相比,单纯注射PO不会增加非致命性过量用药的风险;然而,同时注射PO和海洛因会使风险加倍。这可能反映了使用PO时药物效力和成分的一致性,以及单纯PO注射者的独特特征。我们的研究结果呼吁继续扩大针对注射阿片类药物者(包括PO)的循证过量用药预防干预措施。